Search

Your search keyword '"Sasso E."' showing total 17 results
Start Over Author "Sasso E." Publisher bmj
17 results on '"Sasso E."'

6. AB1243 TRAINING AND VALIDATION OF A MULTIVARIATE PREDICTOR OF RISK OF RADIOGRAPHIC PROGRESSION FOR PATIENTS WITH RHEUMATOID ARTHRITIS

Author

Huizinga, T., primary, Weinblatt, M. E., additional, Shadick, N., additional, Heegaard Brahe, C., additional, Ǿstergaard, M., additional, Hetland, M. L., additional, Saevarsdottir, S., additional, Horton, M., additional, Mabey, B., additional, Flake, D., additional, Ben-Shachar, R., additional, Sasso, E., additional, Gutin, A., additional, Hitraya, E., additional, Lanchbury, J., additional, and Curtis, J., additional

Published
2020
Full Text
View/download PDF

7. FRI0067 Changes in Multi-Biomarker Disease Activity (MBDA) Score Correlate with Changes in Established Disease Activity Measurements in Patients with Early Ra from The Opera Study

Author

Brahe, C.H., primary, Østergaard, M., additional, Johansen, J., additional, Defranoux, N., additional, Hwang, C.-C., additional, Bolce, R., additional, Sasso, E., additional, Hørslev-Petersen, K., additional, Steengaard-Pedersen, K., additional, Junker, P., additional, Ellingsen, T., additional, Ahlquist, P., additional, Lindegaard, H., additional, Linauskas, A., additional, Schlemmer, A., additional, Dam, M.Y., additional, Hansen, I., additional, Lottenburger, T., additional, Ammitzbøll, C., additional, Jørgensen, A., additional, Krintel, S., additional, Raun, J., additional, and Hetland, M.L., additional

Published
2016
Full Text
View/download PDF

13. SAT0012 A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score is Associated with Radiographic Outcomes in RA Patients Treated with TNF Inhibitors

Author

Hirata, S., primary, Li, W., additional, Defranoux, N. A., additional, Bolce, R., additional, Haney, D. J., additional, Sasso, E. H., additional, Kubo, S., additional, Fukuyo, S., additional, Mizuno, Y., additional, Yamaoka, K., additional, Saito, K., additional, and Tanaka, Y., additional

Published
2013
Full Text
View/download PDF

14. FRI0061 Multi-biomarker disease activity (MBDA) score and the 12 individual biomarkers in early rheumatoid arthritis patients relate differentially to clinical response and radiographic progression: results from the swefot trial

Author

Hambardzumyan, K., primary, Saevarsdottir, S., additional, Bolce, R., additional, Forslind, K., additional, Ernestam, S., additional, Petersson, I., additional, Geborek, P., additional, Chernoff, D., additional, Haney, D., additional, Sasso, E. H., additional, and van Vollenhoven, R. F., additional

Published
2013
Full Text
View/download PDF

17. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.

Author

Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, and Medich J

Subjects
Adalimumab, Adult, Analysis of Variance, Antibodies, Monoclonal, Humanized, Arthritis, Psoriatic pathology, Disability Evaluation, Double-Blind Method, Europe, Fatigue drug therapy, Fatigue pathology, Female, Humans, Male, Middle Aged, Pain drug therapy, Pain pathology, Quality of Life, Sickness Impact Profile, Treatment Outcome, United States, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Psoriatic drug therapy, Joints physiopathology, Skin pathology
Abstract

Objective: To evaluate the effects of adalimumab on patient-reported outcomes of joint-related and skin-related functional impairment, health-related quality of life, fatigue and pain in patients with psoriatic arthritis (PsA)., Methods: Patients with moderately- to severely- active PsA were treated with adalimumab, 40 mg, every other week, or placebo, in this 24-week, randomised, controlled trial. Patient-reported outcomes included the Health Assessment Questionnaire Disability Index (HAQ DI), Short-Form 36 Health Survey (SF-36), the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale and the Dermatology Life Quality Index (DLQI)., Results: Adalimumab (n = 151) and placebo (n = 162) groups were comparable with respect to baseline demographics and disease severity. Significant changes from baseline in HAQ DI were reported for adalimumab v placebo (-0.4 v -0.1, p<0.001) at both 12 and 24 weeks. At week 24, significant improvements in the SF-36 domains of physical functioning, role-physical, bodily pain, general health, vitality and social functioning, as well as the physical component summary score, were observed for adalimumab versus placebo (p<0.01). These reported changes in HAQ DI and SF-36 were also clinically important. Significantly more patients treated with adalimumab had complete resolution of functional loss (HAQ DI = 0) and dermatological-related functional limitations (DLQI = 0) compared with placebo at weeks 12 and 24 (p< or =0.001). Adalimumab led to significantly greater improvements in FACIT-Fatigue scores, pain scores, and disease activity measures versus placebo at 12 and 24 weeks (p<0.001 for all)., Conclusions: Adalimumab improved physical-related and dermatological-related functional limitations, HRQOL, fatigue and pain in patients with PsA treated for 24 weeks.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results